JBIO · Jade Biosciences, Inc. · Executive Compensation
$15.31
+0.25 (+1.66%)
At close · Nov 20
Return incl. dividend (before tax)
Going-concern doubt
— cleared Nov 13, 2026
The latest filing no longer states the doubt (first flagged Aug 10, 2026).
View the 10-Q filed Nov 13, 2026Market Cap
$1.06B
Shares
69.19M
Volume · Nov 20
1.02M
Avg daily vol (3M)
911.9K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Tom Frohlich | Chief Executive Officer, President and Director | $9,799,759 |
| Andrew King | President, Research and Development | $4,541,804 |
| Bradford Dahms | Chief Financial Officer | $4,131,991 |
| Timothy P. Noyes | Former Chief Executive Officer | $1,814,483 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Timothy P. Noyes | Former Chief Executive Officer | $3,391,536 |
| Tom Frohlich | Chief Executive Officer, President and Director | $1,364,396 |
| Andrew King | President, Research and Development | $751,605 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Timothy P. Noyes | Chief Executive Officer | $5,305,461 |
| Benjamin T. Dake | President, Chief Operating Officer and Secretary | $2,878,821 |
| George A. Eldridge | Chief Financial Officer | $1,690,904 |
| Hunter Gillies | M.B.Ch.B. Chief Medical Officer | $1,632,478 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Benjamin T. Dake | President, Chief Operating Officer and Secretary | $502,119 |
| Hunter Gillies | M.B.Ch.B. Chief Medical Officer | $423,441 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Mark Eisner, M.D., M.P.H. | Class I director | Appointed | 2026-06-26 |
| Andrew King | President, Research & Development | Appointed | 2026-04-22 |
| Hetal Kocinsky, M.D. | Chief Medical Officer | Resigned | 2025-09-09 |
| Bradford Dahms | Chief Financial Officer and Treasurer | Appointed | 2025-07-01 |
| Eric Dobmeier | Chair of the Board | Appointed | 2025-05-01 |
| Eric Dobmeier | Chair of the Board | Appointed | 2025-05-01 |
| Erin Lavelle | Board of Directors | Appointed | 2025-05-01 |
| Lawrence Klein | Board of Directors | Appointed | 2025-05-01 |
| Tomas Kiselak | Board of Directors | Appointed | 2025-05-01 |
| Tom Frohlich | Board of Directors | Appointed | 2025-05-01 |
| Christopher Cain | Board of Directors | Appointed | 2025-05-01 |
| Eric Dobmeier | Board of Directors | Appointed | 2025-05-01 |
| Elizabeth Balta | General Counsel and Corporate Secretary | Appointed | 2025-05-01 |
| Hetal Kocinsky | the Company's Chief Medical Officer | Appointed | 2025-05-01 |
| Jonathan Quick | the Company's Senior Vice President, Finance and Treasurer | Appointed | 2025-05-01 |
| Andrew King | the Company's Chief Scientific Officer & Head of Research and Development | Appointed | 2025-05-01 |
| George A. Eldridge | Aerovate's Chief Financial Officer | Terminated | 2025-05-01 |
| Tom Frohlich | the Company's Chief Executive Officer | Appointed | 2025-05-01 |
| Timothy P. Noyes | Aerovate's Chief Executive Officer | Terminated | 2025-05-01 |
|
Donald Santel
“On April 28, 2025, Timothy Noyes, Habib Dable, Allison Dorval, David Grayzel, M.D., Mark Iwicki, Joshua Resnick, M.D. and Donald Santel resigned from Aerovate’s board of directors and its committees on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.”
|
Aerovate's board of directors | Resigned | 2025-05-01 |
| Mark Iwicki | Aerovate's board of directors | Resigned | 2025-05-01 |
|
Joshua Resnick
“On April 28, 2025, Timothy Noyes, Habib Dable, Allison Dorval, David Grayzel, M.D., Mark Iwicki, Joshua Resnick, M.D. and Donald Santel resigned from Aerovate’s board of directors and its committees on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.”
|
Aerovate's board of directors | Resigned | 2025-05-01 |
|
David Grayzel
“On April 28, 2025, Timothy Noyes, Habib Dable, Allison Dorval, David Grayzel, M.D., Mark Iwicki, Joshua Resnick, M.D. and Donald Santel resigned from Aerovate’s board of directors and its committees on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.”
|
Aerovate's board of directors | Resigned | 2025-05-01 |
|
Allison Dorval
“On April 28, 2025, Timothy Noyes, Habib Dable, Allison Dorval, David Grayzel, M.D., Mark Iwicki, Joshua Resnick, M.D. and Donald Santel resigned from Aerovate’s board of directors and its committees on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.”
|
Aerovate's board of directors | Resigned | 2025-05-01 |
|
Habib Dable
“On April 28, 2025, Timothy Noyes, Habib Dable, Allison Dorval, David Grayzel, M.D., Mark Iwicki, Joshua Resnick, M.D. and Donald Santel resigned from Aerovate’s board of directors and its committees on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.”
|
Aerovate's board of directors | Resigned | 2025-05-01 |
Leadership
- Tom Frohlich CEO, Board Member
- Eric Dobmeier Chairman, Board Member
- Bradford Dahms CFO
- Benjamin T. Dake COO
- Andrew King CTO
- Elizabeth Balta General Counsel
- Allison Dorval Board Member
- Christopher Cain Board Member
- Continuing Directors Board Member
- Donald J. Santel Board Member
- Erin Lavelle Board Member
- Habib J. Dable Board Member
- Lawrence Klein Board Member
- Mark Eisner, M.D., M.P.H. Board Member
- Tomas Kiselak Board Member
Key facts
CIK
1798749
CUSIP
008064206
13F (30d)
160 filings
151 filers
Visit website
Investor relations